Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

ating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at www.medarex.com.

Medarex Statement on Cautionary Factors: Except for the historical information presented herein, matters discussed herein may constitute forward- looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with ipilimumab development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, risks associated with the use of hazardous substances as well as risks detailed from time
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:7/29/2015)... 2015 The Judicial Panel on Multidistrict Litigation ... to centralize Inferior vena cava (IVC) Filter lawsuits filed ... Medical, have already been centralized by the JPML. ... at risk for a pulmonary embolism. The filters are ... lungs. Claims against Bard and Cook involve incidents of ...
(Date:7/29/2015)...  ViaCyte, Inc., a privately-held regenerative medicine company with the first ... clinical trials, today announced the opening of a second site in ... T olerability, and E fficacy of VC-01™ Combination ... which is the first in Canada , will ... , Alberta.  The lead Edmonton ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/-- LabStyle Innovations Corp. (DRIO), today announced ... national broadcast news segment in Australia . ... following regulatory and reimbursement approval in that country. ... million Australians living with diabetes. As a case in point, ... solution for a 13 year old boy with Type 1 ...
Breaking Medicine Technology:IVC filter litigation continues; law firm provides free information to IVC filter patients 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 2LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 3
... commonly used to treat high blood pressure appear to be ... as stable ischemic heart disease, according to a new comparative ... Quality. A version of the analysis was posted in ... Internal Medicine . , Treatment featuring the two medications -- ...
... Boston Scientific Corporation (NYSE: BSX ) today announced ... as well as guidance for net sales and earnings per ... , Third quarter highlights (Sales growth rates are constant ... billion and achieved adjusted EPS of $0.19, both within the ...
Cached Medicine Technology:High Blood Pressure Medicines Show Promise For Treating Heart Disease 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 27Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 28Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 29
(Date:7/29/2015)... , ... July 29, 2015 , ... This year, the ... precipitation levels this spring. And, where there is water, mold is not far behind. ... offers tips for protecting against water and mold damage. Paul Davis is regularly called ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the Miami Herald ... addiction and mental health disorders. Acu-detox may begin taking off in the South Florida ... and alcohol addiction. Although acupuncture is not a new practice, it is not widely ...
(Date:7/29/2015)... Waukesha, WI (PRWEB) , ... July 29, 2015 ... ... area, Scott Campbell Agency has once again teamed up with Stillwaters Cancer Support ... patients and their families. Stillwaters provides individual and family counseling, support groups, workshops ...
(Date:7/29/2015)... Willingboro, NJ (PRWEB) , ... July 29, 2015 , ... ... Jersey to now offer the Rotation Medical Rotator Cuff System, a new implant to ... “bioinductive” implant is designed to foster natural regeneration of additional tendon tissue, which could ...
(Date:7/29/2015)... ... , ... Today marks a significant achievement in bringing new monies into early ... led by a group of experienced investors, has tapped into an investor community passionate ... be a part of the fund. The Sofia Fund II is now closed ...
Breaking Medicine News(10 mins):Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:Sofia Fund Surpasses Investor Goals 2
... new study released today found blacks remain less likely ... intervention for reducing pain and improving physical function among ... total knee replacements are increasing substantially in both populations. ... the need for healthcare providers and people of all ...
... keep problem from advancing, experts say , , THURSDAY, Feb. 19 ... poorer brain function in people with type 2 diabetes, according ... and older at 52 sites in Canada and the United ... study on cardiovascular risk in diabetes, underwent cognitive tests designed ...
... musical,"In the Heights" and Spanish Broadcasting System,s WPAT-FM 93.1 ... Heart Association,s movement to,educate women about heart health in ... in the Heights", will take place the final week ... "Heart disease is the leading cause of ...
... a Use Not Approved By the Food and Drug ... in two whistleblower suits filed in the Northern District ... its parent company, Johnson & Johnson Inc., alleging that ... use not approved by the Food and Drug Administration ...
... Torchmark Corporation (NYSE: TMK ) announced today ... Financial Officer, Gary Coleman, will present Tuesday, February 24, ... New York City. Torchmark,s presentation is scheduled to ... webcast live at: www.torchmarkcorp.com , on the Investor ...
... was a quiet day at the office, and quite ordinary ... each other throughout the day. Travel Advantage Network employees paid ... one co-worker for the day. Any silenced employees could buy ... unusually quiet day raised more than $100 toward the month,s ...
Cached Medicine News:Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 2Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 3Health News:Out-of-Control Blood Sugar May Affect Memory 2Health News:American Heart Association Makes Broadway Debut This Sunday, Feb 22 2Health News:American Heart Association Makes Broadway Debut This Sunday, Feb 22 3Health News:United States Joins Suits Against Scios and Johnson & Johnson 2Health News:United States Joins Suits Against Scios and Johnson & Johnson 3Health News:Travel Advantage Network Enjoys Silencing Co-Workers, Raising More Than $1,600 for Autism 2
... barrier tips eliminate false signals and ... and tested, Promega Barrier Tips offer ... amplified nucleic acids (PCR(a)), radioactive isotopes, ... and serological specimens. , ,Promega Barrier ...
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , ,Promega Barrier Tips are ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: